UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): June 15, 2011

 

CELLDEX THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware

 

0-15006

 

13-3191702

(State or Other Jurisdiction

 

(Commission File Number)

 

(IRS Employer

of Incorporation)

 

 

 

Identification No.)

 

119 Fourth Avenue

 

 

Needham, Massachusetts

 

02494-2725

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (781) 433-0771

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.07.  Submission of Matters to a Vote of Security Holders

 

Our annual meeting of shareholders was held on June 15, 2011.  Our shareholders elected the following individuals to serve on our board of directors until the annual meeting of shareholders to be held in 2012. The tabulation of votes with respect to the election of such directors was as follows:

 

 

 

For

 

Withheld

 

Broker
Non-Votes

 

Larry Ellberger

 

6,912,322

 

1,600,873

 

17,596,213

 

Anthony S. Marucci

 

6,951,757

 

1,561,438

 

17,596,213

 

Herbert J. Conrad

 

6,992,975

 

1,520,220

 

17,596,213

 

George O. Elston

 

6,935,052

 

1,578,143

 

17,596,213

 

Karen Shoos Lipton

 

7,008,634

 

1,504,561

 

17,596,213

 

Harry H. Penner, Jr.

 

6,931,534

 

1,581,661

 

17,596,213

 

Dr. Timothy M. Shannon

 

7,003,717

 

1,509,478

 

17,596,213

 

 

In addition, our shareholders approved the ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2011. The tabulation of votes with respect to this proposal was as follows:

 

For

 

Against

 

Abstain

 

Broker
Non-Votes

 

23,946,741

 

971,418

 

1,191,249

 

 

 

Our shareholders voted to approve, by non-binding vote, the compensation for our named executive officers. The tabulation of votes with respect to this proposal was as follows:

 

For

 

Against

 

Abstain

 

Broker
Non-Votes

 

6,355,058

 

921,044

 

1,237,093

 

17,596,213

 

 

Finally, our shareholders voted to recommend, by non-binding vote, the preferred frequency of shareholder votes on the compensation of our named executive officers. The tabulation of votes with respect to this proposal was as follows:

 

1 Year

 

2 Years

 

3 Years

 

Abstain

 

Broker
Non-Votes

 

6,146,096

 

198,328

 

836,484

 

1,332,287

 

17,596,213

 

 

With the election of the above-referenced board members on June 15, 2011, Dr. Rajesh Parekh’s term of service on our board of directors ended.  The board of directors of Celldex wishes to express its gratitude to Dr. Parekh for the dedication and guidance he has provided to this company and its board of directors over the years.

 

2



 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

CELLDEX THERAPEUTICS, INC.

 

 

 

 

 

By:

/s/ Avery W. Catlin

 

 

Name: Avery W. Catlin

 

 

Title: Senior Vice President / Chief Financial Officer

 

 

Dated: June 16, 2011

 

3